These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26411180)

  • 1. Atypical Femoral Fractures Can Happen Even With Short Duration Bisphosphonate Treatment.
    Kohli R; Siva C
    Conn Med; 2015 Aug; 79(7):419-22. PubMed ID: 26411180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
    Clout A; Narayanasamy N; Harris I
    J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
    Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
    J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review.
    Bauer DC; Black DM; Dell R; Fan B; Smith CD; Ernst MT; Jurik AG; Frøkjær JB; Boesen M; Vittinghoff E; Abrahamsen B
    J Clin Endocrinol Metab; 2024 Oct; 109(11):e2141-e2150. PubMed ID: 38198798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical fractures: An issue of concern or a myth?
    Al-Ashqar M; Panteli M; Chakrabarty G; Giannoudis PV
    Injury; 2018 Mar; 49(3):649-655. PubMed ID: 29338853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.
    Lee YK; Ahn S; Kim KM; Suh CS; Koo KH
    J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
    Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
    J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
    Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
    J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
    Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC
    Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
    Ing-Lorenzini K; Desmeules J; Plachta O; Suva D; Dayer P; Peter R
    Drug Saf; 2009; 32(9):775-85. PubMed ID: 19670917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of Atypical Femoral Fracture Cases Coupled in a Multicenter Study.
    Zenke Y; Ikeda S; Fukuda F; Tanaka M; Tanaka H; Hirano F; Sakai A
    J UOEH; 2016 Sep; 38(3):207-14. PubMed ID: 27627968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
    Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of atypical femoral fracture during and after bisphosphonate use.
    Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
    Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
    Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
    Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
    Patel VC; Lazzarini AM
    Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.